바로가기 메뉴
본문 바로가기
해더 바로가기
페이지 하단 바로가기

OVERVIEW

Celltrion Pharm’s Growth Knows No End

Celltrion Pharm’s growth continues, along with its efforts for a better future

국내 간장약 단일제품 처방액
1st

Prescribed hepatotonic
medicine in Korea

1st

Godex Cap. ranked 1st
among Korean hepatotonics
in outpatient prescription
(as of 2020)

내용고형제의약품 제조시설 글로벌 GMP획득
1st

Oral solid manufacturing
facility to obtain
GMP certification

1st

Cheongju Plant obtained
the first American and
EuropeanGMP approval
among Korean oral solid
manufacturing facilities.

램시마 국내 누적 매출액
KRW 110 billion

Worth of Remsima
sold in Korea

KRW 110 billion

The domestic cumulative
sales of Remsima,
world’s first
antibody biosimilar,
exceeded KRW 110 billion
(as of February 2020)

국내 유통 바이오의약품
5

Biopharmaceutical
products in Korea

5

Celltrion Pharm holds
distribution rights for
Remsima, Truxima,
Herzuma, Remsima SC,
and CT-P59 in Korea

매출액
KRW 233.5 billion

In revenue

KRW 233.5 billion

Revenue increased by 34.6% from the previous year
(as of 2020)

임직원수
825

Employees

825

The number of employees
increased by 23.5% from
the previous year
(as of December 2020)